SKIN PROTECTION
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
0.0 –5.0 –10.0 –15.0 –20.0 –25.0 –30.0 –35.0 –40.0 –45.0
–28.1 –33.1
–36.9 *
Day 14 Figure 3: Wrinkles count variation.
Additionally, there are some indications for an anti-ageing effect.
Antioxidant Asteriscus graveolens extract assists protecting cells from air pollution induced oxidative stress: reducing the expression of USP15 (down 0.27 folds) and ENC1 (down 0.38 folds) leading to an increased protein accumulation of the antioxidant master regulator NRF2.
Anti-inflammatory Asteriscus graveolens extract protects cells
–42.1 *
Day 28
from inflammatory response following exposure to air pollution through expression reduction of p38 signalling target, the MAPKAPK2 (MK2 down 0.34 folds) that is leading to an attenuated cytokine secretion.
Detoxfication and cell survival Asteriscus graveolens extract protects cells from air pollution induced ER-stress- mediated cell death by reducing the expression of ATF6 (down 0.31 folds) as well as reduction of cell death related gene expression that results in increased cell survival. It stimulates (up 2.03 folds) cytochrome p450 expression and thereby detoxification of hazards.
In vivo – anti-ageing in smoking environment Aim and principle of the study This study intends to assess the anti-ageing and detoxifying effects, as well as to check the compatibility and acceptability and to assess the qualities and efficacy of a cosmetic product, after application under the normal conditions of use. The anti-ageing and detoxifying efficacy
of the product are assessed objectively and quantitatively by instrumental measurements of: l Wrinkles, visible spots, brown spots, UV spots, red spots, porphyrines, pores,
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
* 3.5 3.5 3.3 NS * 3.5 2.8 3.4 NS
0.0 –3.0 –6.0 –9.0 –12.0 –15.0 –18.0 –21.0 –24.0
Day 0 Figure 5: WGS evolution. Day 14 Day 28
5.0 0.0 –5.0 –10.0 –15.0
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
1.2 0.2
–9.7 *
Day 14 Figure 4: Wrinkles volume variation.
and roughness taken in the face, with a VISIA-CA system, before, during and after treatment.
l Wrinkles and skin roughness, obtained in the periocular (eye) area and in the corner of the mouth with a Fringe projection system (Primos 3D), before, during and after treatment.
l Skin firmness and elasticity taken in the periocular (eye) area and in the corner of the mouth, with a Cutometer (Dual- Cutometer MPA 580), before, during and after treatment.
l Skin hydration obtained in the periocular area and in the corner of the mouth, with a Corneometer (Dual-Cutometer MPA 580), before, during and after treatment.
l Skin barrier function (trans epidermal water loss – TEWL) obtained with a Tewameter 300 in each hemiface, before, during and after treatment.
l Skin colour distribution obtained in the hemiface with a Chromameter (Chromameter CR-400) under a D65 illuminant, before, during and after treatment.
And quantitatively by clinical evaluation of clinical scores obtained by a dermatologist, or the technician, under his authority, before, during and after the treatment.
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
0.0
–4.7 NS
–3.8
–12.0 *
Day 28
–20.3 *
Day 14 Figure 6: WGS variation. September 2015 PERSONAL CARE 57 Day 28
www.natashahazimphotography.com Wrinkle grading score Change (%)
Change (%)
Change (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
